Testing effectiveness (Phase 2)Study completedNCT04263090
What this trial is testing
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Who this might be right for
Non-small Cell Lung CancerAdenocarcinomaStage IV
Icahn School of Medicine at Mount Sinai 25